Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P14784 (
IL-2 receptor
)
3,849
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
There has been interest in the potential of synthetic compounds to modify immune responses by imitation of cytokine action. Direct administration of interleukin 2 (IL-2) in conjunction with adoptive transfer of lymphokine activated killer cells has been used in the treatment of cancer, but there are toxic effects resulting from the high doses of IL-2 required. We have developed a new synthetic compound, ammonium tri-chloro(dioxoethylene-O,O'-)tellurate (
AS-101
), which has immunomodulating properties and minimal toxicity. The effects of
AS-101
on the activation and function of immunocompetent cells have been assessed. We have found that
AS-101
induces proliferation and IL-2 production by human lymphocytes in vitro, and enhances the production of IL-2 and colony-stimulating factor by mouse spleen cells. Splenocytes of BALB/c mice injected with
AS-101
increased production of IL-2 and CSF in vitro in the presence of mitogen. Mononuclear cells of normal donors acquired responsiveness to recombinant IL-2 and bound monoclonal antibody to
IL-2 receptor
after incubation with
AS-101
. Splenocytes of mice treated in vivo with
AS-101
expressed high levels of
IL-2 receptor
. The stimulation of lymphocytes by
AS-101
apparently involves an increase in intracellular free calcium.
AS-101
administered systemically to mice mediated antitumour effects which could be attributable to its immunomodulatory properties. In addition,
AS-101
could directly enhance the ratio of OKT4 to OKT8-positive cells in cultured mononuclear cells from AIDS (acquired immune deficiency syndrome) patients. These results indicate that
AS-101
is potentially useful in the treatment of clinical conditions involving immunosuppression.
...
PMID:A new immunomodulating compound (AS-101) with potential therapeutic application. 311 16
AS-101
(ammonium trichloro[dioxoethylene-O,O'-]tellurate) is a newly developed synthetic compound with immunomodulating properties and minimal toxicity. We evaluated the effects of
AS-101
on various parameters of the activation and function of immunocompetent cells.
AS-101
induced
IL-2 receptor
expression, IL-2 production and proliferation by human and mouse lymphocytes in vitro and enhanced the production colony-stimulating factor (CSF) by mouse spleen cells. In vivo treatment of Balb/c mice with
AS-101
caused a significantly increased production of IL-2 and CSF in vitro in the presence of mitogen. When administered systemically to mice,
AS-101
mediated antitumor effects in vivo. These results suggest that
AS-101
is an active biological response modifier, which might have potential use in the treatment of conditions such as malignancy, AIDS and some types of immune deficiency.
...
PMID:The biological activity and immunotherapeutic properties of AS-101, a synthetic organotellurium compound. 326 21
Cytokines are known to play a major role in the pathogenesis of mycosis fungoides, a cutaneous malignant neoplasm of CD 4 T cells. In the present study, we investigated the effect of AS101, a tellurium-based compound with immunomodulating properties, on the pattern of lymphokine production by peripheral blood mononuclear cells (PBMCs) from patients with mycosis fungoides. PBMCs were isolated from 35 patients with mycosis fungoides stage IA and IB before initiation of treatment and from 20 healthy sex and age-matched controls. Unstimulated and phytohaemagglutinin-stimulated PBMCs were tested with and without the addition of AS101. The production of interferon-gamma, interleukin 2 (IL-2),
IL-2 receptor
(IL-2R), interleukin 5 (IL-5) and interleukin 10 (IL-10) was determined by enzyme-linked immunosorbent assays. The effects of
AS-101
on mycosis fungoides PBMCs were compared to those of healthy donor PBMCs. Significantly higher levels of IL-2R, IL-5 and IL-10 and significantly lower levels of interferon-gamma were found in the patients compared to the controls. There was no significant difference between the groups in the production of IL-2. AS101 inhibited the production of IL-2R, IL-5 and IL-10 and induced a significant increase in IL-2 levels in the mycosis fungoides PBMCs. These findings may have important clinical implications for the possible therapeutic benefit of AS101 in mycosis fungoides.
...
PMID:Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. 1172 Jan 71
